Frequently Asked Questions

Here are some answers to common questions about Ferring products. For more information, you can consult the Prescribing Information for the product or reach out to a Ferring representative.

MENOPUR is administered as a subcutaneous injection for the development of multiple follicles and pregnancy in the ovulatory patients participating in an Assisted Reproductive Technology (ART) program.

MENOPUR is contraindicated in women who have: a high FSH level indicating primary ovarian failure, presence of uncontrolled non-gonadal endocrinopathies, tumors of the pituitary gland or hypothalamus, sex hormone dependent tumors of the reproductive tract and accessory organs, abnormal uterine bleeding of undetermined origin, ovarian cysts or enlargement of undetermined origin, not due to polycystic ovary syndrome, or prior hypersensitivity to menotropins or MENOPUR. MENOPUR is not indicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman.

The recommended dosing scheme for patients undergoing IVF follows a stepwise approach and is individualized for each woman.

Beginning on cycle day 2 or 3, administer a starting dose of 225 International Units of MENOPUR subcutaneously daily. Adjust the dose after 5 days based on the woman’s ovarian response, as determined by ultrasound evaluation of follicular growth and serum estradiol levels.

Do not make additional dosage adjustments more frequently than every 2 days or by more than 150 International Units at each adjustment.

Continue treatment until adequate follicular development is evident, and then administer hCG. Withhold the administration of hCG in cases where the ovarian monitoring suggests an increased risk of OHSS on the last day of MENOPUR therapy.

Therapy should not exceed 20 days.

Instruct women on the correct usage and dosing of MENOPUR. Caution women not to change the dosage or the schedule of administration unless told to do so by her healthcare provider.

MENOPUR is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Ovarian torsion has been reported after gonadotropin treatment. Serious pulmonary conditions and thromboembolic events have been reported with MENOPUR. There have been infrequent reports of ovarian neoplasms with MENOPUR. Multiple pregnancies, spontaneous abortion, congenital malformations and ectopic pregnancies have occurred following treatment with MENOPUR.

The most common adverse reactions (≥2%) in ART include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS.

MENOPUR is supplied in sterile vials as a lyophilized, white to off-white powder or pellet.

Each vial of MENOPUR is accompanied by a vial of sterile diluent containing 2 mL of 0.9% Sodium Chloride for Injection, USP.

The lyophilized powder may be stored refrigerated or at room temperature (3° to 25° C/37° to 77°F) until dispensed. Protect from light. Use immediately after reconstitution. Discard unused material.

FYREMADEL is administered as a subcutaneous injection for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.

FYREMADEL is supplied in disposable, ready for use, single-dose, sterile, prefilled 1 mL glass syringes containing 250 mcg/0.5 mL aqueous solution of ganirelix acetate.

FYREMADEL is contraindicated under the following conditions:

  • Known hypersensitivity to ganirelix acetate or to any of its components
  • Known hypersensitivity to GnRH or any other GnRH analog
  • Known or suspected pregnancy

After initiating FSH therapy on Day 2 or 3 of the cycle, FYREMADEL may be administered subcutaneously once daily during the mid to late portion of the follicular phase. By taking advantage of endogenous pituitary FSH secretion, the requirement for exogenously administered FSH may be reduced. Treatment with FYREMADEL should be continued daily until the day of hCG administration.

The most common adverse events (≥ 1%) in completed controlled clinical studies were gynecological abdominal pain, fetal death, headache, ovarian hyperstimulation syndrome, vaginal bleeding, injection site reaction, and nausea.

Cases of hypersensitivity reactions, including anaphylactoid reactions, have been reported, as early as with the first dose, during postmarketing surveillance.

FYREMADEL prefilled syringes should be stored at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). Protect from light.

NOVAREL is a human chorionic gonadotropin (hCG) used to trigger ovulation in women whose infertility is not due to primary ovulation failure, and who has been appropriately pretreated with human menotropins.

NOVAREL comes in a vial as a sterile powder and is injected intramuscularly by the patient after reconstitution with Bacteriostatic Water for Injection preserved with benzyl alcohol 0.9%.

NOVAREL should not be used in patients with prior allergic reaction to HCG. HCG may cause fetal harm when administered to a pregnant woman.

5,000 to 10,000 USP Units one day following the last dose of menotropins.

Adverse reactions include headache, irritability, restlessness, depression, fatigue, edema, precocious puberty, gynecomastia, pain at the site of injection. Hypersensitivity reactions both localized and systemic in nature, including erythema, urticaria, rash, angioedema, dyspnea and shortness of breath, have been reported. The relationship of these allergic-like events to the polypeptide hormone or the diluent containing benzyl alcohol is not clear.

The principal serious adverse reactions when using NOVAREL are:

  • Ovarian hyperstimulation, a syndrome of sudden ovarian enlargement, ascites with or without pain, and/or pleural effusion
  • Enlargement of preexisting ovarian cysts or rupture of ovarian cysts with resultant hemoperitoneum
  • Multiple births
  • Arterial thromboembolism

Store at room temperature at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (between 59° and 86°F).

Refrigerate the reconstituted product at 2° to 8°C (36° to 46°F) and use within 30 days.

ENDOMETRIN is a vaginal insert indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women.

ENDOMETRIN should not be used in individuals with any of the following conditions: previous allergic reactions to progesterone or any of the ingredients of ENDOMETRIN, undiagnosed vaginal bleeding, known missed abortion or ectopic pregnancy, liver disease, known or suspected breast cancer, active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.

ENDOMETRIN should not be recommended for use with other vaginal products (such as antifungal products) as this may alter progesterone release and absorption from the vaginal insert.

The dose of ENDOMETRIN is 100 mg administered vaginally two or three times daily starting the day after oocyte retrieval and continuing for up to 10 weeks total duration.

  • The physician should be alert to earliest signs of myocardial infarction, cerebrovascular disorders, arterial or venous thromboembolism (venous thromboembolism or pulmonary embolism), thrombophlebitis, or retinal thrombosis. ENDOMETRIN should be discontinued if any of these are suspected
  • Patients with a history of depression need to be closely observed. Consider discontinuation if symptoms worsen
  • The most common adverse reactions reported (greater than 5%) were post-oocyte retrieval pain, abdominal pain, nausea, and ovarian hyperstimulation syndrome

Each ENDOMETRIN (progesterone) Vaginal Insert, 100 mg, is packed individually in a sealed foil pouch. Store at 20 ‐ 25˚C (68 ‐ 77˚F); excursions permitted between 15 ‐ 30°C (59 ‐ 86°F).

MENOPUR® (menotropins for injection)

Indication for Use

  • MENOPUR® (menotropins for injection), administered subcutaneously, is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an Assisted Reproductive Technology (ART) program. 

Important Safety Information

  • MENOPUR is contraindicated in women who have: a high FSH level indicating primary ovarian failure, presence of uncontrolled non-gonadal endocrinopathies, tumors of the pituitary gland or hypothalamus, sex hormone dependent tumors of the reproductive tract and accessory organs, abnormal uterine bleeding of undetermined origin, ovarian cysts or enlargement of undetermined origin, not due to polycystic ovary syndrome, or prior hypersensitivity to menotropins or MENOPUR. MENOPUR is not indicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman
  • MENOPUR should only be used by physicians who are thoroughly familiar with infertility problems. MENOPUR is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Ovarian torsion has been reported after gonadotropin treatment. Serious pulmonary conditions and thromboembolic events have been reported with MENOPUR. There have been infrequent reports of ovarian neoplasms with MENOPUR. Multiple pregnancies, spontaneous abortion, congenital malformations and ectopic pregnancies have occurred following treatment with MENOPUR.
  • The most common adverse reactions (≥2%) in ART include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 1.800.FDA.1088.

Please see full Prescribing Information.

FYREMADEL® (ganirelix acetate) injection

Indication for Use

  • FYREMADEL® (ganirelix acetate) injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.

Important Safety Information

  • Ganirelix acetate injection is contraindicated under the following conditions: Known hypersensitivity to ganirelix acetate or to any of its components, Known hypersensitivity to GnRH or any other GnRH analog, Known or suspected pregnancy.
  • Ganirelix acetate injection should be prescribed by physicians who are experienced in infertility treatment. Before starting treatment with ganirelix acetate, pregnancy must be excluded. Safe use of ganirelix acetate during pregnancy has not been established.
  • Special care should be taken in women with signs and symptoms of active allergic conditions.
  • Cases of hypersensitivity reactions, including anaphylactoid reactions, have been reported, as early as with the first dose, during postmarketing surveillance. In the absence of clinical experience, ganirelix acetate treatment is not advised in women with severe allergic conditions.
  • The packaging of this product contains natural rubber latex which may cause allergic reactions.
  • Most commonly reported adverse reactions (≥ 1%) reported in clinical trials were: Abdominal Pain (gynecological), Fetal Death, Headache, Ovarian Hyperstimulation Syndrome, Vaginal Bleeding, Injection Site Reaction, Nausea, Abdominal Pain (gastrointestinal).
  • During post marketing surveillance, rare cases of hypersensitivity reactions, including anaphylactoid reactions, have been reported, as early as with the first dose.
  • Major and minor congenital abnormalities have been reported in clinical follow-up studies of newborns of women administered ganirelix acetate injection. The causal relationship between these congenital anomalies and ganirelix acetate is unknown.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 1.800.FDA.1088.

Please see full Prescribing Information.

NOVAREL® (chorionic gonadotropin for injection, USP)

Indication for Use

  • NOVAREL is indicated for the induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pre-treated with human menotropins. 

Important Safety Information

  • NOVAREL should not be used in patients with prior allergic reaction to HCG. HCG may cause fetal harm when administered to a pregnant woman. 
  • NOVAREL should be used in conjunction with human menopausal gonadotropins only by physicians experienced with infertility problems who are familiar with the criteria for patient selection, contraindications, warnings, precautions, and adverse reactions described in the package insert for menotropins. The principal serious adverse reactions during this use are: (1) Ovarian hyperstimulation, a syndrome of sudden ovarian enlargement, ascites with or without pain, and/or pleural effusion; (2) Enlargement of preexisting ovarian cysts or rupture of ovarian cysts with resultant hemoperitoneum; (3) Multiple births, and (4) Arterial thromboembolism.
  • Anaphylaxis has been reported with urinary-derived HCG products.
  • Since androgens may cause fluid retention, HCG should be used with caution in patients with cardiac or renal disease, epilepsy, migraine, or asthma.
  • HCG can cross react in the radioimmunoassay of gonadotropins, especially luteinizing hormone. Each individual laboratory should establish the degree of cross reactivity with their gonadotropin assay. Physicians should make the laboratory aware of patients on HCG if gonadotropin levels are requested.
  • Defects of forelimbs and of the central nervous system, as well as alterations in sex ratio, have been reported in mice on combined gonadotropin and HCG regimens. The dose of gonadotropin used was intended to induce superovulation. No mutagenic effect has been clearly established in humans.
  • It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when HCG is administered to a nursing woman.
  • Adverse reactions include headache, irritability, restlessness, depression, fatigue, edema, precocious puberty, gynecomastia, pain at the site of injection. Hypersensitivity reactions both localized and systemic in nature, including erythema, urticaria, rash, angioedema, dyspnea and shortness of breath, have been reported. The relationship of these allergic-like events to the polypeptide hormone or the diluent containing benzyl alcohol is not clear.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 1.800.FDA.1088.

Please see full Prescribing Information.

ENDOMETRIN® (progesterone) Vaginal Insert

Indication for Use

  • ENDOMETRIN® (progesterone) Vaginal Insert is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women. 

Important Safety Information

  • ENDOMETRIN should not be used in individuals with any of the following conditions: previous allergic reactions to progesterone or any of the ingredients of ENDOMETRIN, undiagnosed vaginal bleeding, known missed abortion or ectopic pregnancy, liver disease, known or suspected breast cancer, active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events. 
  • The physician should be alert to earliest signs of myocardial infarction, cerebrovascular disorders, arterial or venous thromboembolism (venous thromboembolism or pulmonary embolism), thrombophlebitis, or retinal thrombosis. ENDOMETRIN should be discontinued if any of these are suspected.
  • Patients with a history of depression need to be closely observed. Consider discontinuation if symptoms worsen.
  • ENDOMETRIN should not be recommended for use with other vaginal products (such as antifungal products) as this may alter progesterone release and absorption from the vaginal insert.
  • The most common adverse reactions reported (greater than 5%) were post-oocyte retrieval pain, abdominal pain, nausea, and ovarian hyperstimulation syndrome.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 1.800.FDA.1088.

Please see full Prescribing Information.